Trial Profile
Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms BIOMARKER
- 15 Aug 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 Oct 2018 to 1 Jul 2020.
- 16 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Jul 2019.